ImmunityBio Inc (NASDAQ: IBRX) is 5.98% higher on its value in year-to-date trading and has touched a low of $1.25 and a high of $6.93 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The IBRX stock was last observed hovering at around $5.37 in the last trading session, with the day’s loss setting it -0.05%.
Currently trading at $5.32, the stock is 0.56% and 16.23% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.69 million and changing -0.93% at the moment leaves the stock 67.21% off its SMA200. IBRX registered 195.56% gain for a year compared to 6-month gain of 232.50%. The firm has a 50-day simple moving average (SMA 50) of $6.54k and a 200-day simple moving average (SMA200) of -$9.33.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 12.47% loss in the last 1 month and extending the period to 3 months gives it a 2.11%, and is -12.36% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.49% over the week and 10.08% over the month.
ImmunityBio Inc (IBRX) has around 628 employees, a market worth around $3.59B and $0.62M in sales. Profit margin for the company is -93761.41%. Distance from 52-week low is 325.60% and -23.23% from its 52-week high. The company has generated returns on investments over the last 12 months (-201.17%).
ImmunityBio Inc quarterly earnings per share for the current quarter are estimated at -$0.16 with sales reaching $20k over the same period.The EPS is expected to grow by 40.87% this year, but quarterly earnings will post 1,456.30% year-over-year. Quarterly sales are estimated to shrink -94.40% in year-over-year returns.
ImmunityBio Inc (IBRX) Top Institutional Holders
214 institutions hold shares in ImmunityBio Inc (IBRX), with institutional investors hold 43.45% of the company’s shares. The shares outstanding are 670.87M, and float is at 131.91M with Short Float at 40.37%. Institutions hold 8.85% of the Float.
The top institutional shareholder in the company is Vanguard Group Inc with over 10.33 million shares valued at $28.73 million. The investor’s holdings represent 1.55% of the IBRX Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 9.5 million shares valued at $26.41 million to account for 1.42% of the shares outstanding. The other top investors are State Street Corporation which holds 2.78 million shares representing 0.42% and valued at over $7.72 million, while Geode Capital Management, LLC holds 0.41% of the shares totaling 2.73 million with a market value of $7.59 million.
ImmunityBio Inc (IBRX) Insider Activity
The most recent transaction is an insider purchase by BLASZYK MICHAEL D,the company’sDirector. SEC filings show that BLASZYK MICHAEL D bought 71,915 shares of the company’s common stock on Jun 05 ’23 at a price of $2.75 per share for a total of $0.2 million. Following the purchase, the insider now owns 71915.0 shares.
ImmunityBio Inc disclosed in a document filed with the SEC on Jun 02 ’23 that Brennan John Owen (Director) bought a total of 25,000 shares of the company’s common stock. The trade occurred on Jun 02 ’23 and was made at $2.83 per share for $70700.0. Following the transaction, the insider now directly holds 25000.0 shares of the IBRX stock.
Still, SEC filings show that on Jun 01 ’23, Clark Wesley (Director) acquired 7,000 shares at an average price of $2.91 for $20370.0. The insider now directly holds 8,000 shares of ImmunityBio Inc (IBRX).
